Meeting
2016 ASCO Annual Meeting
Phase I study of mTORC1/2 inhibitor BI 860585 as single agent or with exemestane or paclitaxel in patients with advanced solid tumors.
Authors
Filippo G. De Braud
Istituto Naz. Tumori-Fond. IRCCS- Oncologia Medica, Milan, Italy
Filippo G. De Braud , Jean-Pascal H. Machiels , Marcello Tiseo , Sylvie Rottey , Matteo Duca , Marie Laruelle , Stefania Salvagni , Lore Lapeire , Laura Manfreda , Céline Veau , Daniela Fischer , Mahmoud Ould-Kaci
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Other Novel Agents
Clinical Trial Registration Number
NCT01938846
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2545)
DOI
10.1200/JCO.2016.34.15_suppl.2545
Abstract #
2545
Poster Bd #
245
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
Poster
2023 ASCO Annual Meeting
A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).
First Author: Mohamed Shanshal
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.
First Author: Jing Huang
Poster
2015 ASCO Annual Meeting
A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.
First Author: Rebecca Sophie Kristeleit